Liver transplantation for HCV-associated liver cirrhosis: Predictors of outcomes in a population with significant genotype 3 and 4 distribution

Liver Transplantation

Volumn 9, Issue 4, 2003, Pages 339-347

  Zekry, A ^a   Whiting, P ^b   Crawford, D H ^b   Angus, P W ^c   Jeffrey, G P ^d   Padbury, R T ^e   Gane, E J ^f   McCaughan, Geoffrey W ^a   Koorey, D ^g   Strasser, S ^g   Verran, D ^g   Stewart, G ^g   Lynch, S ^g   Fawcett, J ^g   Strong, R ^g   Gow, P ^g   Berry, R ^g   Jones, R ^g   Dolan, P ^g   Kow, L ^g   Harley, H ^g   House, A ^g   Mictchell, A ^g   Jeffrey, G ^g   Munn, S ^g   McCall, J ^g   more..

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

^c AUSTIN HEALTH   (Australia)

^d SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^e FLINDERS MEDICAL CENTRE   (Australia)

^f AUCKLAND CITY HOSPITAL   (New Zealand)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AZATHIOPRINE; CYCLOSPORIN; HEPATITIS C ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; OKT 3; PREDNISONE; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; AGE; AGED; ALCOHOL CONSUMPTION; ARTICLE; AUSTRALIA; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENOTYPE; GRAFT FAILURE; GRAFT INFECTION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEW ZEALAND; ORGAN DONOR; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; RECIPIENT; REINFECTION; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

EID: 0344519762     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2003.50063     Document Type: Article

References (25)

1. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, et al. HCV-related fibrosis progression following liver transplantation: Increase in recent years. J Hepatol 2000;32:673-684.
2. Prieto M, Berenguer M, Rayon JM, Cordoba J, Arguello L, Carrasco D, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: Relationship with rejection episodes. Hepatology 1999;29:250-256.
3. Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, Lake J, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998;28:823-830.
4. Rosen HR, Gretch DR, Oehlke M, Flora KD, Benner KG, Rabkin JM, et al. Timing and severity of initial hepatitis C recurrence as predictors of long-term liver allograft injury. Transplantation 1998;65:1178-1182.
5. Feray C, Caccamo L, Alexander GJ, Ducot B, Gugenheim J, Casanovas T, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology 1999;117:619-625.
6. Berenguer M, Prieto M, Cordoba J, Rayon JM, Carrasco D, Olaso V, et al. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection. J Hepatol 1998;28:756-763.
7. Rosen HR, Shackleton CR, Higa L, Gralnek IM, Farmer DA, McDiarmid SV, et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 1997;92:1453-1457.
8. Feray C, Gigou M, Samuel D, Paradis V, Mishiro S, Maertens G, et al. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology 1995;108:1088-1096.
9. Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Maertens G, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996;334:815-820.
10. Zhou S, Terrault NA, Ferrell L, Hahn JA, Lau JY, Simmonds P, et al. Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: Relationship to genotype and level of viremia. Hepatology 1996;24:1041-1046.
11. Berenguer M, Prieto M, San Juan F, Rayon JM, Martinez F, Carrasco D, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002;36:202-210.
12. Busquets J, Xiol X, Figueras J, Jaurrieta E, Torras J, Ramos E, et al. The impact of donor age on liver transplantation: Influence of donor age on early liver function and on subsequent patient and graft survival. Transplantation 2001;71:1765-1771.
13. Burak KW, Kremers WK, Batts KP, Wiesner RH, Rosen CB, Razonable RR, et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002;8:362-369.
14. Chen J, McGuinness PH, Koorey DJ, Rickard K, Wylie B, McCaughan GW. Hepatitis C virus genotypes in a cohort of Australian blood donors and haemophiliac and liver transplant patients. J Gastro Hepatol 1997;12:182-187.
15. McGuinness PH, Bishop GA, Painter DM, Chan R, McCaughan GW. Intrahepatic hepatitis C RNA levels do not correlate with degree of liver injury in patients with chronic hepatitis C. Hepatology 1996;23:676-687.
16. Gayowski T, Singh N, Marino IR, Vargas H, Wagener M, Wannstedt C, et al. Hepatitis C virus genotypes in liver transplant recipients: impact on posttransplant recurrence, infections, response to interferon-alpha therapy and outcome. Transplantation 1997;64:422-426.
17. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: Quasispecies and genotypes. Semin Liver Dis 1995; 15:41-63.
18. Argentini C, Dettori S, Villano U, Guadagnino V, Infantolino D, Dentico P, et al. Molecular characterisation of HCV genotype 4 isolates circulating in Italy. J Med Virol 2000;62:84-90.
19. Khan MH, Farrell GC, Byth K, Lin R, Weltman M, George J, et al. Which patients with hepatitis C develop liver complications? Hepatology 2000;31:513-520.
20. Zylberberg H, Chaix ML, Brechot C. Infection with hepatitis C virus genotype 4 is associated with a poor response to interferon-alpha. Ann Intern Med 2000;132:845-846.
21. Ray SC, Arthur RR, Carella A, Bukh J, Thomas DL. Genetic epidemiology of hepatitis C virus throughout Egypt. J Infect Dis 2000;182:698-707.
22. Deschenes M, Forbes C, Tchervenkov J, Barkun J, Metrakos P, Tector J, et al. Use of older donor livers is associated with more extensive ischemic damage on intraoperative biopsies during liver transplantation. Liver Transpl Surg 1999;5:357-361.
23. Burra P, Mioni D, Cecchetto A, Cillo U, Zanus G, Fagiuoli S, et al. Histological features after liver transplantation in alcoholic cirrhotics. J Hepatol 2001;34:716-722.
24. Bellamy CO, DiMartini AM, Ruppert K, Jain A, Dodson F, Torbenson M, et al. Liver transplantation for alcoholic cirrhosis: Long-term follow-up and impact of disease recurrence. Transplantation 2001;72:619-626.
25. Pera M, Garcia-Valdecasas JC, Grande L, Rimola A, Fuster J, Lacy AM, et al. Liver transplantation for alcoholic cirrhosis with anti-HCV antibodies. Transpl Int 1997;10:289-292.